Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate Cancer

home / insights / updates-on-use-of-genomic-testing-in-patients-with-high-risk-clinically-localized-prostate

Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.

© 2024 MJH Life Sciences

All rights reserved.